Trump says envoy Witkoff had productive meeting with Putin
On Tuesday, H.C. Wainwright analysts reiterated a Buy rating for Arcus Biosciences stock (NYSE: NYSE:RCUS) and maintained a price target of $24.00, significantly above the current trading price of $9.22. According to InvestingPro data, analysts’ targets range from $12 to $46, with a strong consensus Buy recommendation. The decision follows the presentation of initial combination data for casdatifan (cas) and cabozantinib (cabo) in treating IO-experienced clear cell renal cell carcinoma (ccRCC) at the American Society of Clinical Oncology (ASCO) meeting last weekend.
Arcus Biosciences showcased promising results from a cohort of 42 patients, focusing on the feasibility and safety required for the FDA to initiate the PEAK-1 Phase 3 trial. Of these patients, 24 were evaluated for efficacy after at least 12 weeks of follow-up. The treatment involved administering 100 mg QD cas, the selected dose for Phase 3, alongside 60 mg QD cabo. The company maintains a strong financial position with more cash than debt and a healthy current ratio of 5.37, though InvestingPro analysis indicates rapid cash burn remains a concern.
The trial aimed to enroll patients who had not previously been treated with cabozantinib, resulting in a lower rate of prior TKI treatment. The confirmed overall response rate (ORR) was 46%, including one complete response and ten partial responses. Additionally, 50% of patients achieved stable disease, with a low progression disease rate of 4%.
The analysts emphasized that the combination treatment demonstrated synergy in response rates without added toxicity. The median follow-up was 5.3 months, during which all responders continued to show positive responses. The analysts highlighted the potential for additional partial responses over time, especially given the nature of HIF2α inhibitors. For deeper insights into RCUS’s valuation and growth prospects, including 10+ additional ProTips and comprehensive financial analysis, visit InvestingPro.
In other recent news, Arcus Biosciences reported its Q1 2025 earnings, revealing a larger-than-expected loss with earnings per share at -1.14, missing the forecast of -1.02. The company’s revenue also fell short, reaching $28 million against a projected $38.61 million. Despite these financial setbacks, Arcus Biosciences maintains a strong cash position of $1 billion, which is expected to support its ongoing development activities. The company is focusing on advancing its product pipeline, particularly its collaboration with AstraZeneca (NASDAQ:AZN) in renal cell carcinoma treatments. Analysts have noted the strategic importance of these collaborations for Arcus Biosciences’ future growth. Additionally, Arcus Biosciences plans to maintain its full-year 2025 revenue guidance between $75 million and $90 million. The company is also addressing high research and development expenses, which are anticipated to peak this year. These developments are part of Arcus Biosciences’ broader strategy to leverage its substantial cash reserves and strategic partnerships for long-term growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.